Editas Medicine, Inc. is a pharmaceutical company based in the United States. With an ESG score of 25.2, the company is considered to have a medium risk assessment. Specializing in genome editing, Editas Medicine focuses on developing innovative genomic medicines to address various serious diseases. Utilizing CRISPR/Cas9 technology, the company works on a proprietary genome editing platform that aims to revolutionize the healthcare industry. Editas Medicine is dedicated to advancing sustainable and impactful solutions in the field of healthcare through its genome editing technology.